1
|
Ghiviriga I. Nuclear Magnetic Resonance Method for Measuring Water Solubility of Organic Compounds. Anal Chem 2023; 95:2706-2712. [PMID: 36705621 DOI: 10.1021/acs.analchem.2c03277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Water solubility measurements are required in drug discovery, in toxicological or environmental studies, and in developing industrial processes which employ extractions or crystallizations. The gold-standard shake-flask method is tedious and takes at least 24 h. We developed a nuclear magnetic resonance (NMR) method for automation, which has the same accuracy and solubility range as the shake-flask method, but a measurement can be made faster, since the analysis does not require separation of the phases. Samples of saturated solutions are analyzed in the presence of excess solute, since the NMR spectra do not show signals for the dispersed solids, and they tend to show separate signals for the dissolved and dispersed liquids. Spectra are acquired with water suppression, using a pulse sequence appropriate for quantitation. A sample of water is used as the external reference, and the concentration of the solute is determined using the PULCON relationship. An evaluation of the method in terms of selectivity, accuracy, precision, and limit of quantitation is presented in detail.
Collapse
Affiliation(s)
- Ion Ghiviriga
- Center for NMR Spectroscopy, Chemistry Department, University of Florida, Gainesville, Florida32611-7200, United States
| |
Collapse
|
2
|
Zhang K, Liu Y, Tang Y. Screening of TNFR1 Binding Peptides from Deinagkistrodon acutus Venom through Phage Display. Toxins (Basel) 2022; 14:toxins14020155. [PMID: 35202182 PMCID: PMC8878721 DOI: 10.3390/toxins14020155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 02/07/2022] [Accepted: 02/16/2022] [Indexed: 02/04/2023] Open
Abstract
The venomous species Deinagkistrodon acutus has been used as anti-inflammatory medicine in China for a long time. It has been proven to have anti-inflammatory activity, but its specific anti-inflammatory components have not yet been fully elucidated. Tumor necrosis factor receptor-1 (TNFR1), which participates in important intracellular signaling pathways, mediates apoptosis, and functions as a regulator of inflammation, is often used as the target to develop anti-inflammatory drugs. The small peptides of snake venom have the advantages of weak immunogenicity and strong activity. To obtain the specific TNFR1 binding peptides, we constructed a T7 phage library of D. acutus venom glands, and then performed biopanning against TNFR1 on the constructed library. After biopanning three times, several sequences with potential binding capacity were obtained and one 41-amino acid peptide was selected through a series of biological analyses including sequence length, solubility, and simulated affinity, named DAvp-1. After synthesis, the binding capacity of DAvp-1 and TNFR1 was verified using surface plasmon resonance technology (SPR). Conclusively, by applying phage display technology, this work depicts the successful screening of a promising peptide DAvp-1 from D. acutus venom that binds to TNFR1. Additionally, our study emphasizes the usefulness of phage display technology for studies on screening natural product components.
Collapse
Affiliation(s)
- Kangran Zhang
- Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China;
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Yang Liu
- Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China;
- Correspondence: (Y.L.); (Y.T.)
| | - Yezhong Tang
- Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China;
- Correspondence: (Y.L.); (Y.T.)
| |
Collapse
|
3
|
Cosgrove B, Down K, Bertrand S, Tomkinson NCO, Barker MD. Investigating the effects of the core nitrogen atom configuration on the thermodynamic solubility of 6,5-bicyclic heterocycles. Bioorg Med Chem Lett 2021; 33:127752. [PMID: 33359169 DOI: 10.1016/j.bmcl.2020.127752] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 12/11/2020] [Accepted: 12/13/2020] [Indexed: 01/25/2023]
Abstract
Physicochemical properties, such as solubility, are important when prioritising compounds for progression on a drug discovery project. There is limited literature around the systematic effects of core changes on thermodynamic solubility. This work details the synthesis of nitrogen containing 6,5-bicyclic heterocyclic cores which are common scaffolds in medicinal chemistry and the analysis of their physicochemical properties, particularly, thermodynamic solubility. Crystalline solids were obtained where possible to enable a robust comparison of the thermodynamic solubility. Other parameters such as pKa, melting point and lipophilicity were also measured to determine the key factors affecting the observed solubility.
Collapse
Affiliation(s)
- Brett Cosgrove
- Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, UK; Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK
| | - Kenneth Down
- Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
| | - Sophie Bertrand
- Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
| | | | - Michael D Barker
- Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
| |
Collapse
|
4
|
Water-soluble inhibitors of ABCG2 (BCRP) - A fragment-based and computational approach. Eur J Med Chem 2020; 210:112958. [PMID: 33199153 DOI: 10.1016/j.ejmech.2020.112958] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 10/16/2020] [Accepted: 10/18/2020] [Indexed: 12/13/2022]
Abstract
A good balance between hydrophilicity and lipophilicity is a prerequisite for all bioactive compounds. If the hydrophilicity of a compound is low, its solubility in water will be meager. Many drug development failures have been attributed to poor aqueous solubility. ABCG2 inhibitors are especially prone to be insoluble since they have to address the extremely large and hydrophobic multidrug binding site in ABCG2. For instance, our previous, tariquidar-related ABCG2 inhibitor UR-MB108 (1) showed high potency (79 nM), but very low aqueous solubility (78 nM). To discover novel potent ABCG2 inhibitors with improved solubility we pursued a fragment-based approach. Substructures of 1 were optimized and the fragments 'enlarged' to obtain inhibitors, supported by molecular docking studies. Synthesis was achieved, i.a., via Sonogashira coupling, click chemistry and amide coupling. A kinetic solubility assay revealed that 1 and most novel inhibitors did not precipitate during the short time period of the applied biological assays. The solubility of the compounds in aqueous media at equilibrium was investigated in a thermodynamic solubility assay, where UR-Ant116 (40), UR-Ant121 (41), UR-Ant131 (48) and UR-Ant132 (49) excelled with solubilities between 1 μM and 1.5 μM - an up to 19-fold improvement compared to 1. Moreover, these novel N-phenyl-chromone-2-carboxamides inhibited ABCG2 in a Hoechst 33342 transport assay with potencies in the low three-digit nanomolar range, reversed MDR in cancer cells, were non-toxic and proved stable in blood plasma. All properties make them attractive candidates for in vitro assays requiring long-term incubation and in vivo studies, both needing sufficient solubility at equilibrium. 41 and 49 were highly ABCG2-selective, a precondition for developing PET tracers. The triple ABCB1/C1/G2 inhibitor 40 qualifies for potential therapeutic applications, given the concerted role of the three transporter subtypes at many tissue barriers, e.g. the BBB.
Collapse
|
5
|
Turcano L, Battista T, De Haro ET, Missineo A, Alli C, Paonessa G, Colotti G, Harper S, Fiorillo A, Ilari A, Bresciani A. Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme. PLoS Negl Trop Dis 2020; 14:e0008339. [PMID: 32437349 PMCID: PMC7269337 DOI: 10.1371/journal.pntd.0008339] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 06/03/2020] [Accepted: 04/30/2020] [Indexed: 11/19/2022] Open
Abstract
Trypanothione reductase (TR) is a key enzyme that catalyzes the reduction of trypanothione, an antioxidant dithiol that protects Trypanosomatid parasites from oxidative stress induced by mammalian host defense systems. TR is considered an attractive target for the development of novel anti-parasitic agents as it is essential for parasite survival but has no close homologue in humans. We report here the identification of spiro-containing derivatives as inhibitors of TR from Trypanosoma brucei (TbTR), the parasite responsible for Human African Trypanosomiasis. The hit series, identified by high throughput screening, was shown to bind TbTR reversibly and to compete with the trypanothione (TS2) substrate. The prototype compound 1 from this series was also found to impede the growth of Trypanosoma brucei parasites in vitro. The X-ray crystal structure of TbTR in complex with compound 1 solved at 1.98 Å allowed the identification of the hydrophobic pocket where the inhibitor binds, placed close to the catalytic histidine (His 461’) and lined by Trp21, Val53, Ile106, Tyr110 and Met113. This new inhibitor is specific for TbTR and no activity was detected against the structurally similar human glutathione reductase (hGR). The central spiro scaffold is known to be suitable for brain active compounds in humans thus representing an attractive starting point for the future treatment of the central nervous system stage of T. brucei infections. Trypanosoma brucei is a parasite responsible for neglected pathologies such as human African trypanosomiasis, also known as sleeping sickness. This disease is endemic in sub-Saharan Africa, with 70 million people at risk of infection. Current treatments for this type of disease are limited by their toxicity, administration in endemic countries and treatment resistance. Therapies against infectious diseases typically rely on targeting one or more components of the parasite that are not present in humans to ensure the best possible therapeutic window. In this case we aimed at targeting the Trypanosoma brucei trypanothione reductase (TR), one enzyme that synthesize the reduced trypanothione a key molecule for preserving the parasite redox balance. This enzyme does not exist in humans that have glutathione instead of trypanothione. Past attempts to identify novel inhibitors of this target has failed to generate drug-like molecules. To overcome this limitation we employed a recent, higher quality, TR activity assay to test a collection of compounds previously reported to be active against these parasites. This approach led to the identification and validation of a new chemotype with a unique mode of inhibition of TR. This chemical series is a drug-like starting point, in fact its core (spiro) is present in drugs approved for human use.
Collapse
Affiliation(s)
- Lorenzo Turcano
- Department of Translational and Discovery Research, Pomezia (Roma) Italy
| | - Theo Battista
- Dipartimento di Scienze Biochimiche, Sapienza Università di Roma, Roma, Italy
| | | | - Antonino Missineo
- Department of Translational and Discovery Research, Pomezia (Roma) Italy
| | - Cristina Alli
- Department of Translational and Discovery Research, Pomezia (Roma) Italy
| | - Giacomo Paonessa
- Department of Translational and Discovery Research, Pomezia (Roma) Italy
| | - Gianni Colotti
- Istituto di Biologia e Patologia Molecolari del CNR c/o Dipartimento di Scienze Biochimiche, Sapienza Università di Roma, Roma, Italy
| | | | - Annarita Fiorillo
- Dipartimento di Scienze Biochimiche, Sapienza Università di Roma, Roma, Italy
| | - Andrea Ilari
- Istituto di Biologia e Patologia Molecolari del CNR c/o Dipartimento di Scienze Biochimiche, Sapienza Università di Roma, Roma, Italy
- * E-mail: (AI); (AB)
| | - Alberto Bresciani
- Department of Translational and Discovery Research, Pomezia (Roma) Italy
- * E-mail: (AI); (AB)
| |
Collapse
|
6
|
Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discov Today 2020; 25:969-982. [PMID: 32298797 DOI: 10.1016/j.drudis.2020.03.012] [Citation(s) in RCA: 74] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 03/03/2020] [Accepted: 03/16/2020] [Indexed: 12/30/2022]
Abstract
Targeted protein degraders are an emerging modality. Their properties fall outside the traditional small-molecule property space and are in the 'beyond rule of 5' space. Consequently, drug discovery programs focused on developing orally bioavailable degraders are expected to face complex drug metabolism and pharmacokinetics (DMPK) challenges compared with traditional small molecules. Nevertheless, little information is available on the DMPK optimization of oral degraders. Therefore, in this review, we discuss our experience of these DMPK optimization challenges and present methodologies and strategies to overcome the hurdles dealing with this new small-molecule modality, specifically in developing oral degraders to treat cancer.
Collapse
|
7
|
The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors. Molecules 2019; 24:molecules24234319. [PMID: 31779228 PMCID: PMC6930638 DOI: 10.3390/molecules24234319] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 11/18/2019] [Accepted: 11/21/2019] [Indexed: 01/14/2023] Open
Abstract
Colchicine site ligands suffer from low aqueous solubility due to the highly hydrophobic nature of the binding site. A new strategy for increasing molecular polarity without exposing polar groups—termed masked polar group incorporation (MPGI)—was devised and applied to nitrogenated combretastatin analogues. Bulky ortho substituents to the pyridine nitrogen hinder it from the hydrophobic pocket while increasing molecular polarity. The resulting analogues show improved aqueous solubilities and highly potent antiproliferative activity against several cancer cell lines of different origin. The more potent compounds showed moderate tubulin polymerization inhibitory activity, arrested the cell cycle of treated cells at the G2/M phase, and subsequently caused apoptotic cell death represented by the cells gathered at the subG0/G1 population after 48 h of treatment. Annexin V/Propidium Iodide (PI) double-positive cells observed after 72 h confirmed the induction of apoptosis. Docking studies suggest binding at the colchicine site of tubulin in a similar way as combretastatin A4, with the polar groups masked by the vicinal substituents. These results validate the proposed strategy for the design of colchicine site ligands and open a new road to increasing the aqueous solubility of ligands binding in apolar environments.
Collapse
|
8
|
Könczöl Á, Dargó G. Brief overview of solubility methods: Recent trends in equilibrium solubility measurement and predictive models. DRUG DISCOVERY TODAY. TECHNOLOGIES 2018; 27:3-10. [PMID: 30103861 DOI: 10.1016/j.ddtec.2018.06.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 05/31/2018] [Accepted: 06/03/2018] [Indexed: 06/08/2023]
Abstract
Solubility is a crucial physicochemical parameter affecting the whole process of drug discovery and development. Thus, understanding of the methods and concepts to measure and predict this propensity are of utmost importance for the pharmaceutical scientist. Despite their inherent limitations, kinetic solubility screening methods became routine assays by mimicking bioassay conditions and guiding the lead optimization process. In contrast, thermodynamic solubility methods show a clear evolution: miniaturized high throughput assays coupled to analytical techniques such as solid-state characterization, ultra performance liquid chromatography, or polychromatic turbidimetry, have been developed, thereby enabling a more complex physicochemical profiling at the early discovery stage. Solubility prediction still poses a significant challenge at the industrial level. Classification and critical evaluation of recent in silico models are provided. Discussion of experimental and computational methods: was based on relevant industrial references.
Collapse
Affiliation(s)
- Árpád Könczöl
- Compound Profiling Laboratory, Gedeon Richter Plc., H-1475 Budapest, Hungary.
| | - Gergő Dargó
- Compound Profiling Laboratory, Gedeon Richter Plc., H-1475 Budapest, Hungary; Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Műegyetem rakpart 3, H-1111 Budapest, Hungary
| |
Collapse
|
9
|
Walker MA. Improvement in aqueous solubility achieved via small molecular changes. Bioorg Med Chem Lett 2017; 27:5100-5108. [PMID: 29100802 DOI: 10.1016/j.bmcl.2017.09.041] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 09/14/2017] [Accepted: 09/17/2017] [Indexed: 10/18/2022]
Abstract
Overcoming poor solubility is a significant issue in drug discovery. The most common solution is to replace carbon atoms with polar heteroatoms such as N and O or by attaching a solubilizing appendage. This approach can lead to other issues such as poor activity and PK or the increased risk for toxicity. However, there are more subtle structural changes which can be employed that lead to an increase in solubility. These include, excising hydrophobic groups which do not efficiently contribute to binding, modifying stereo- and regiochemistry, increasing or decreasing the degree of unsaturation or adding small hydrophobic groups such as fluorine or methyl.
Collapse
Affiliation(s)
- Michael A Walker
- Dart Neuroscience, 12278 Scripps Summit Dr., San Diego, CA 92131, USA.
| |
Collapse
|
10
|
Yao H, Liu J, Xu S, Zhu Z, Xu J. The structural modification of natural products for novel drug discovery. Expert Opin Drug Discov 2016; 12:121-140. [DOI: 10.1080/17460441.2016.1272757] [Citation(s) in RCA: 96] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Hong Yao
- State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China
| | - Junkai Liu
- State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China
| | - Shengtao Xu
- State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China
| | - Zheying Zhu
- Division of Molecular Therapeutics & Formulation, School of Pharmacy, The University of Nottingham, Nottingham, UK
| | - Jinyi Xu
- State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China
| |
Collapse
|